Outcome of Board Meeting

Date: 04th November, 2026 Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001. Mumbai - 400 051. Security Code: 532815 Symbol: SMSPHARMA Dear Sir/Madam, Subject: Outcome of Board Meeting, Financial Results and Disclosure under Regulation 30 read with Schedule III of the SEBI (LODR) Regulations, 2015: With reference to the cited subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e., 04th November, 2026, have inter- alia, transacted the following item(s) of the Agenda: 1. Financial Results: Approved the standalone and consolidated un-audited Financial Results along with Limited Review Report for for the quarter and half-year ended 30th September, 2026. Pursuant to Regulation 33 of the SEBI Listing Regulations, Statement of un-audited (Standalone & Consolidated) Financial Results along with the limited review report issued by Statutory Auditors of the Company for the quarter and half year ended on 30th September, 2026 is enclosed. 2. Resignation of Company Secretary & Compliance Officer Mr. Thirumalesh Tumma (ICSI M.No A35824) Company Secretary & Compliance Officer and Key Managerial Personnel of the Company has tendered his resignation due to personal reasons. The Board has considered and approved his resignation with effect from close of business hours of 4th November, 2026. Accordingly, he shall be relieved from his duties with effect from closure of business hours on 4th November, 2026. Further, he has confirmed that there are no other material reasons for the resignation other than those provided in his resignation letter. The copy of resignation letter is enclosed herewith as Annexure-I Disclosure required under Regulation 30 of the SEBI (LODR) Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure – II. 3. Appointment of Company Secretary & Compliance Officer Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors has approved the appointment of Mr. Manohar Mollama (ICSI M.No. F11904), as a Company Secretary & Compliance Officer and Key Managerial Personnel of the Company of the company with effect from 5th November, 2026. Disclosure required under Regulation 30 of the SEBI (LODR) Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 is enclosed herewith as Annexure – III. The meeting commenced at 11:30 a.m. and concluded at about 01:10 p.m. Please take the above intimation on your records. Thanking you Yours faithfully For SMS Pharmaceuticals Limited Ramesh Babu Potluri Managing Director DIN: 00166381 SURYANARAYANA & SURESH CA- Flat # C1, Milienium House, # 8-2-601/B, Road No. 10, Near Zaheer Nagar Cross Road, Chartered Accountants Banjara Hills, Hyderabad - 500 034. I NOlA 2r040-23386783/35164367 all suryanarayanasuresh@gmail.com Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEB) (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended The Board of Directors SMS Pharmaceuticals Limited Hyderabad. 'yVe have revie\,ved the accompanying statement of unaudited financial results of SMS Pharmaceuticals Limited ("the Company"), for the quarter and half year ended 30lh September 2026 ('the statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. This statement which is the responsibility of the Company's Management and approved by tile Board of Directors, has been prepared in accordance with the recognition and measuren1ent principles laid down in the lndian Accounting Standard 34 "Interim Financial Reporting" Ind AS 3ol"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generaIIy accepted in lndia. Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Revic\'\" of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered /\ccountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe thclt the accornpanying statement of unaudited financial results prepared in accordance \vith the aforesaid indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SElll (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that ilcontains any material misstatement. For Suryanarayana & Suresh. Chartered Accountants M. No. 224319 Place: I-Iyderclbad Da Ie: 0~.11.2026 UU1N: 26224319ANXIKW.\25:1 SMS PHARMACEUTICALS LIMITED (CIN : L24239TG1987PLC008066) Regd. Office: 8th Floor, Trendset Jayabheri Connect, Kondapur,Serilingampally, Ranga Reddy Dist., Hyderabad-500084,Telangana, India. Tel: +91-40-6985 9999, Fax :+91-40-2525 9889; Email: complianceofficer@smspharma.com Standalone Statement of Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026 (Rs. In Lakhs) Quarter ended Half Year ended Year Ended S.No Particulars 30/09/2026 30/06/2026 30/09/2025 30/09/2026 30/09/2025 31/03/2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 Income (a) Revenue from Operations 31,607.41 20,696.49 24,242.95 52,303.90 43,847.66 88,687.10 (b) Other Income 133.92 174.44 143.39 308.36 202.70 835.38 Total Income 31,741.33 20,870.93 24,386.34 52,612.26 44,050.36 89,522.48 2 Expenses (a) Cost of Materials Consumed 16,924.26 13,572.13 10,493.83 30,496.39 25,085.37 51,687.27 (b) Changes in Inventories. 1,197.14 (2,384.73) 3,326.43 (1,187.59) (242.40) (2,284.17) (c) Manufacturing Expenses 2,479.92 1,951.54 2,573.49 4,431.46 4,546.21 9,070.22 (d) Employee Benefits Expense 2,691.90 2,330.42 1,925.14 5,022.32 3,743.63 8,792.34 (e) Finance Cost 573.57 549.95 573.62 1,123.52 1,157.66 2,307.56 (f) Depreciation and Amortization Expense 1,032.48 999.08 1,002.06 2,031.56 1,977.31 3,991.93 (g) Other Expenses 1,589.31 1,038.12 1,086.22 2,627.43 1,990.85 4,330.20 Total Expenses -(a to g) 26,488.58 18,056.51 20,980.79 44,545.09 38,258.63 77,895.35 3 Profit/(loss) Before Exceptional and Extraordinary Items and Tax (1-2) 5,252.75 2,814.42 3,405.55 8,067.17 5,791.73 11,627.13 4 Exceptional items - . - - - - - 5 Profit/(loss)Before Extraordinary Items and Tax (3-4) 5,252.75 2,814.42 3,405.55 8,067.17 5,791.73 11,627.13 6 Extraordinary Items - - - - - - 7 Profit/(Ioss) Before Tax (5-6) 5,252.75 2,814.42 3,405.55 8,067.17 5,791.73 11,627.13 8 Tax Expenses (a) Current Tax relating to Current Period 1,292.00 610.00 825.00 1,902.00 1,325.00 2,598.00 (b) Current Tax relating to Earlier Period - - - - - (4.69) (c) Deferred Tax 47.28 91.16 66.25 138.44 131.68 272.89 Total Tax Expense 1,339.28 701.16 891.25 2,040.44 1,456.68 2,866.20 9 Net Profit / (Loss) after Tax (7-8) 3,913.47 2,113.26 2,514.30 6,026.73 4,335.05 8,760.93 10 Other Comprehensive Income (OCI): 9 Items that will not be reclass [Showing first 8,000 characters — download PDF for full document]